NOEMA PHARMA ANNOUNCES NOE-105 (GEMLAPODECT) PHASE 2A STUDY IN TOURETTE SYNDROME MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Reuters · 10/17 12:03

Please log in to view news